专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06194411B1 3(2H)-pyridazinone derivatives and pharmaceutical compositions containing these compounds 失效
标题翻译： 3（2H） - 哒嗪酮衍生物和含有这些化合物的药物组合物
公开(公告)号：US06194411B1
公开(公告)日：2001-02-27
申请号：US08973584
申请日：1998-07-20
申请人： Péter Mátyus , László Hársing , Mariann née Tapfer Karim , Judit Kosáry , Ágnes née Behr Papp , Antal Simay , Yemane Tilahun , Éva née Joszt Tomori , Edit Horváth , Katalin Horváth , Ildikó Varga , Erzsébet née Kaczián Zára , Margit née Iglóy Bidló , Alice Druga , György Rabloczky , Márta Varga , Egon Kárpáti , Endre Kasztreiner , István Király , Ildikó née Gyóry Máthé , György Máthé , László Sebestyén , Nándor Makk
发明人： Péter Mátyus , László Hársing , Mariann née Tapfer Karim , Judit Kosáry , Ágnes née Behr Papp , Antal Simay , Yemane Tilahun , Éva née Joszt Tomori , Edit Horváth , Katalin Horváth , Ildikó Varga , Erzsébet née Kaczián Zára , Margit née Iglóy Bidló , Alice Druga , György Rabloczky , Márta Varga , Egon Kárpáti , Endre Kasztreiner , István Király , Ildikó née Gyóry Máthé , György Máthé , László Sebestyén , Nándor Makk
IPC分类号： A61K31501
CPC分类号： C07D405/12 , C07D319/20
摘要： The invention relates to R-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazionone of formula (1) and to S-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazionone of formula (2) and to acid-addition salts thereof as well as pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds. The new starting compounds of formula (4) and (5) are also involved in the scope of the invention. The compounds according to the invention possess &agr;1- and &agr;2-adrenoceptor antagonistic effects and urogenital selectivity. Thus, they are useful for the treatment of the benign prostate hyperplasia.
摘要翻译：本发明涉及式（1）的R-2- [3 - （[1,4]苯并二恶烷-2-基甲基氨基）-1-丙基] -3（2H） - 哒嗪酮和S-2- [3- 具有式（2）的[1,4]苯并二恶烷-2-基甲基氨基）-1-丙基] -3（2H） - 哒嗪酮及其酸加成盐以及含有这些化合物的药物组合物。此外，本发明涉及制备上述化合物的方法。式（4）和（5）的新起始化合物也参与本发明的范围。根据本发明的化合物具有α1-和α2-肾上腺素受体拮抗作用和泌尿生殖选择性。因此，它们可用于治疗良性前列腺增生。

2. 发明授权

US06248907B1 N-([1,4]benzodioxan-2-ylmethyl)-N-(3-chloro-1-propyl)-amine 失效
标题翻译： N - （[1,4]苯并二恶烷-2-基甲基）-N-（3-氯-1-丙基） - 胺
公开(公告)号：US06248907B1
公开(公告)日：2001-06-19
申请号：US09649077
申请日：2000-08-28
申请人： Péter Mátyus , László Hársing , Marianne Tapfer née Karim , Judit Kosáry , Ágnes Papp née Behr , Antal Simay , Yemane Tilahun , Éva Tomori née Joszt , Edit Horváth , Katalin Horváth , Ildikó Varga , Erzsébet Zára née Kaczián , Margit Bidló née Iglóy , Alice Druga , György Rabloczky , Márta Varga , Egon Kárpáti , Endre Kasztreiner , István Király , Ildikó Máthé née Gyóry , György Máthé , László Sebestyén , Nándor Makk
发明人： Péter Mátyus , László Hársing , Marianne Tapfer née Karim , Judit Kosáry , Ágnes Papp née Behr , Antal Simay , Yemane Tilahun , Éva Tomori née Joszt , Edit Horváth , Katalin Horváth , Ildikó Varga , Erzsébet Zára née Kaczián , Margit Bidló née Iglóy , Alice Druga , György Rabloczky , Márta Varga , Egon Kárpáti , Endre Kasztreiner , István Király , Ildikó Máthé née Gyóry , György Máthé , László Sebestyén , Nándor Makk
IPC分类号： C07D31914
CPC分类号： C07D405/12 , C07D319/20
摘要： The invention relates to R-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (1), and to S-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (2), and to acid-addition salts thereof as well as pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds. The new starting compounds of formulae (4) and (5) are also involved in the scope of the invention. The compounds according to the invention possess &agr;1- and &agr;2-adrenoceptor antagonistic effects and urogenital selectivity. Thus, they are useful for the treatment of the benign prostate hyperplasia.
摘要翻译：本发明涉及式（1）的R-2- [3 - （[1,4]苯并二恶烷-2-基甲基氨基）-1-丙基] -3（2H） - 哒嗪酮，以及S-2- [3- （2）的（[1,4]苯并二恶烷-2-基甲基氨基）-1-丙基] -3（2H） - 哒嗪酮及其酸加成盐以及含有这些化合物的药物组合物。此外，本发明涉及制备上述化合物的方法。式（4）和（5）的新起始化合物也参与本发明的范围。根据本发明的化合物具有α1-和α2-肾上腺素受体拮抗作用和泌尿生殖选择性。因此，它们可用于治疗良性前列腺增生。

3. 发明授权

US06265445B1 Antiarrhythmic compounds 失效
标题翻译：抗心律不齐的化合物
公开(公告)号：US06265445B1
公开(公告)日：2001-07-24
申请号：US09555602
申请日：2000-07-28
申请人： Gyula Papp , András Varró , Péter Mátyus , Ildikó Varga , Tivadar Rettegi , Alice Druga , Antal Simay , Imre Moravcsik , Pál Berzsenyi , Daniella Barlocco , Giorgio Cignarella , Márta Pátfalusi
发明人： Gyula Papp , András Varró , Péter Mátyus , Ildikó Varga , Tivadar Rettegi , Alice Druga , Antal Simay , Imre Moravcsik , Pál Berzsenyi , Daniella Barlocco , Giorgio Cignarella , Márta Pátfalusi
IPC分类号： A61K3117
CPC分类号： C07C233/36 , C07C217/18 , C07C233/78 , C07C275/40 , C07C311/08 , C07C335/20 , Y10S514/821
摘要： The present invention relates to novel, antiarrhythmically active phenoxyalkylamine derivatives possessing a double point of attack. More particularly, the present invention relates to new phenoxyalkylamine derivatives of the formula (1) wherein R1 and R2, independently from each other, mean hydrogen, halogen or C1-4 alkyl group; R3, R4 and R5, independently from each other, stand for hydrogen or C1-4 alkyl group; R6 represents hydrogen, C1-4 alkyl or benzyl group; R7 means nitro group or amino group optionally monosubstituted by C1-4 alkyl, benzoyl, C1-4 alkylcarbonyl, C1-4 alkylsulfonyl, C1-4 alkylcarbamoyl or C1-4 alkylthiocarbamoyl group; both n and m are 0 or 1, with the proviso that R2 is different from hydrogen, when R1 is hydrogen, as well as stereoisomers or mixtures of stereoisomers thereof, acid addition salts thereof and hydrates, prodrugs and metabolites of all these compounds.
摘要翻译：本发明涉及具有双重攻击点的新型抗心律失活的苯氧基烷基胺衍生物。更具体地说，本发明涉及式（1）的新的苯氧基烷基胺衍生物，其中R 1和R 2彼此独立地表示氢，卤素或C 1-4烷基; R 3，R 4和R 5彼此独立地代表氢或C 1-4烷基; R 6表示氢，C 1-4烷基或苄基; R 7表示硝基或任选被C 1-4烷基，苯甲酰基，C 1-4烷基羰基，C 1-4烷基磺酰基，C 1-4的单取代的氨基烷基氨基甲酰基或C 1-4烷基硫代氨基甲酰基; n和m均为0或1，条件是当R 1为氢时，R 2不同于氢，以及立体异构体或其立体异构体的混合物，其酸加成盐和水合物，前药和所有这些化合物的代谢物。

4. 发明授权

US06323197B1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors 失效
标题翻译：缩合2,3-苯并二氮杂衍生物及其作为AMPA受体抑制剂的用途
公开(公告)号：US06323197B1
公开(公告)日：2001-11-27
申请号：US09117508
申请日：1998-11-05
申请人： Ernese Csuzdi , Tamas Hámori , Gizella Ábrahám , Sändor Sólyom , István Tarnawa , Pál Berzsenyi , Ferenc Andrási , István Ling , Antal Simay , Melinda Gál , Katalin Horváth , Eszter Szentkuti , Márta Szöllosy , István Pallagi
发明人： Ernese Csuzdi , Tamas Hámori , Gizella Ábrahám , Sändor Sólyom , István Tarnawa , Pál Berzsenyi , Ferenc Andrási , István Ling , Antal Simay , Melinda Gál , Katalin Horváth , Eszter Szentkuti , Márta Szöllosy , István Pallagi
IPC分类号： C07D49114
CPC分类号： C07D487/04 , C07D491/04 , C07D491/14
摘要： The invention concerns compounds of formula (I), in which R1, R2, R3 and R4 mean hydrogen or different substituents; X means hydrogen or halogen; Y means C1-6 alkoxy or X and Y together mean —O—(CH2)n—O—; n means 1, 2 or 3; and A together with nitrogen forms a saturated or unsaturated five-member heterocycle which can contain between 1 and 3 nitrogen atoms and/or an oxygen atom and/or one or two carbonyl groups. Owing to their non-competitive inhibiting of the AMPA receptors, these compounds can be used as medicaments for treating diseases of the central nervous system.
摘要翻译：本发明涉及式（I）化合物，其中R 1，R 2，R 3和R 4表示氢或不同的取代基; X表示氢或卤素; Y表示C1-6烷氧基或X和Y一起表示-O-（CH 2）n -O-; n表示1,2或3; 并且A与氮一起形成可含有1至3个氮原子和/或氧原子和/或一个或两个羰基的饱和或不饱和五元杂环。由于它们对AMPA受体的非竞争性抑制，这些化合物可以用作治疗中枢神经系统疾病的药物。

5. 发明授权

US06482819B1 2,3-benzodiazepine derivatives 失效
标题翻译： 2,3-苯并二氮杂衍生物
公开(公告)号：US06482819B1
公开(公告)日：2002-11-19
申请号：US09463440
申请日：2000-04-10
申请人： Gizella Ábrahám , Emese Csuzdi , Sándor Sólyom , Pál Berzsenyi , István Tarnawa , Ferenc Andrási , István Ling , Tamás Hámori , Katalin Horváth , Imre Moravcsik , István Pallagi , Antal Simay
发明人： Gizella Ábrahám , Emese Csuzdi , Sándor Sólyom , Pál Berzsenyi , István Tarnawa , Ferenc Andrási , István Ling , Tamás Hámori , Katalin Horváth , Imre Moravcsik , István Pallagi , Antal Simay
IPC分类号： A61K31551
CPC分类号： C07D487/04
摘要： 2,3-Benzodiazepines of formula (I), their stereoisomers and acid addition salts, wherein the variables have the meaning given in the specification, and pharmaceutical compositions containing them which are suitable for treating conditions associated with muscle spasms, epilepsy as well as acute and chronic forms of neurodegenerative diseases are disclosed.
摘要翻译：式（I）的2,3-苯并二氮杂，其立体异构体和酸加成盐，其中变量具有本说明书中给出的含义，以及含有它们的药物组合物，其适用于治疗与肌肉痉挛，癫痫以及急性并且公开了慢性形式的神经变性疾病。

6. 发明授权

US06200970B1 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors 失效
标题翻译： 2,3-苯并二氮杂衍生物及其作为AMPA受体抑制剂的用途
公开(公告)号：US06200970B1
公开(公告)日：2001-03-13
申请号：US09125008
申请日：1998-11-05
申请人： István Ling , Gizella Ábrahám , Sándor Sólyom , Tamás Hámori , István Tarnawa , Pál Berzsenyi , Ferenc Andrási , Emese Csuzdi , Márta Szöllósy , Antal Simay , István Lagi , Katalin Horváth
发明人： István Ling , Gizella Ábrahám , Sándor Sólyom , Tamás Hámori , István Tarnawa , Pál Berzsenyi , Ferenc Andrási , Emese Csuzdi , Márta Szöllósy , Antal Simay , István Lagi , Katalin Horváth
IPC分类号： A61K31551
CPC分类号： C07D243/02
摘要： A compound of formula I in which X means hydrogen or halogen, Y means —NR3— or —N═, R1 and R2 are the same or different and mean hydrogen, C1-C6 alkyl, nitro, halogen, the group —NR8R9, —O—C1-4 alkyl, —CF3, OH or C1-6 alkanoyloxy, R3 means hydrogen, the group —CO—R10, C1-6 alkyl or C3-7 cycloalkyl, R4 means optionally substituted C1-C6 alkyl, R5 means hydrogen or R4 and R5 together mean oxygen, R6 means C1-4 alkyl, R8 and R9 are the same or different and mean hydrogen, C1-C6 alkyl or —CO—C1-6 alkyl, R10 means hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-10 aryl, the group —NR11R12, —O—C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl or —O—C3-7 cycloalkyl, R11 and R12 are the same or different and mean hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C6-10 aryl and —C...C... means a double bond or single bonds or an isomer or physiologically compatible salt thereof with the proviso that the compound is not 1-(3-chlorophenyl)-4-methyl-8-methoxy, 5H-2,3-benzodiazepine.
摘要翻译：式Iin化合物，其中X表示氢或卤素，Y表示-NR3-或-N =，R1和R2相同或不同，表示氢，C1-C6烷基，硝基，卤素，-NR8R9基，-O- C 1-4烷基，-CF 3，OH或C 1-6烷酰氧基，R 3表示氢，-CO-R 10，C 1-6烷基或C 3-7环烷基，R 4表示任选取代的C 1 -C 6烷基，R 5表示氢或R 4， R5一起表示氧，R6表示C1-4烷基，R8和R9相同或不同，表示氢，C1-C6烷基或-CO-C1-6烷基，R10表示氢，任选取代的C 1 -C 6烷基，任选取代 C6-10芳基，基团-NR11R12，-O-C1-6烷基，C3-7环烷基，C2-6烯基或-O-C3-7环烷基，R11和R12相同或不同，表示氢，任选取代 C 1 -C 6烷基或任选取代的C 6-10芳基和C 1 -C 6表示双键或单键，其是异构体或其生理上相容的盐，条件是所述化合物不是1-（3-氯苯基） -4-甲基-8-甲氧基，5H-2,3-苯并二苯基氮杂

7. 发明授权

US06600036B2 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors 失效
标题翻译：缩合2,3-苯并二氮杂衍生物及其作为AMPA受体抑制剂的用途
公开(公告)号：US06600036B2
公开(公告)日：2003-07-29
申请号：US09993646
申请日：2001-11-27
申请人： Ernese Csuzdi , Tamas Hamori , Gizella Abraham , Sandor Solyom , Istvan Tarnawa , Pal Berzsenyi , Ferenc Andrasi , Istvan Ling , Antal Simay , Melinda Gal , Katalin Horvath , Eszter Szentkuti , Marta Szollosy , Istvan Pallagi
发明人： Ernese Csuzdi , Tamas Hamori , Gizella Abraham , Sandor Solyom , Istvan Tarnawa , Pal Berzsenyi , Ferenc Andrasi , Istvan Ling , Antal Simay , Melinda Gal , Katalin Horvath , Eszter Szentkuti , Marta Szollosy , Istvan Pallagi
IPC分类号： C07D24310
CPC分类号： C07D487/04 , C07D491/04 , C07D491/14
摘要： Compounds of formula I are described, their production and use in pharmaceutical agents.
摘要翻译：描述了式I化合物，其制备和在药剂中的用途。

8. 发明授权

US4435567A Process for preparing substituted urea derivatives 失效
标题翻译：制备取代脲衍生物的方法
公开(公告)号：US4435567A
公开(公告)日：1984-03-06
申请号：US334470
申请日：1981-12-28
申请人： Gyorgy Lugosi , Antal Simay , Janos Bodnar , Laszlo Simandi , Eva Somfai
发明人： Gyorgy Lugosi , Antal Simay , Janos Bodnar , Laszlo Simandi , Eva Somfai
IPC分类号： C07D295/20 , C07C67/00 , C07C239/00 , C07C273/18 , C07C275/02 , C07C275/06 , C07C275/26 , C07C275/28 , C07C275/30 , C07C275/34 , C07D213/75 , C07D217/06 , C07D235/32 , C07D275/06 , C07D277/82 , C07D285/12 , C07D285/135 , C07D295/215 , C07C127/00 , C07C127/15 , C07C127/17 , C07C127/19
CPC分类号： C07D213/75 , C07C273/1809 , C07D217/06 , C07D235/32 , C07D277/82 , C07D285/135 , C07D295/215
摘要： A process for the preparation of substituted urea derivatives, and compositions and concentrates for the same purpose are disclosed. According to the process the substituted urea derivatives of formula (I) ##STR1## wherein R is hydrogen, alkyl, aryl, cycloalkyl or aralkyl, R.sup.1 and R.sup.2 are hydrogen, alkyl, alkenyl, alkinyl, alkoxy, oxyalkyl, cycloalkyl, aralkyl, alkoxycarbonylalkyl, aryl or heteroaryl, or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom may form a saturated or unsaturated heterocycle, or a condensed and/or substituted ring system, and said heterocycle or said condensed and/or substituted ring system may contain also a sulfo group,can be manufactured by reacting an amine of formula (II) ##STR2## with an N-carbamoyl-benzoic acid sulfimide derivative of formula (III) ##STR3## The disclosed N-acylating composition comprises of from 3 to 60% by weight, preferably of from 5 to 50% by weight sulfimide derivative of formula (III), of from 97 to 40% by weight, preferably of from 95 to 50% by weight solvent, and if desired, an organic or inorganic base.The disclosed N-acylating concentrate comprises of from 60 to 95.5% by weight N-acylating agent of formula (III) and of from 4.5 to 40% by weight additives.
摘要翻译：公开了用于制备取代的脲衍生物的方法，以及用于相同目的的组合物和浓缩物。根据该方法，式（I）的取代脲衍生物其中R是氢，烷基，芳基，环烷基或芳烷基，R1和R2是氢，烷基，烯基，炔基，烷氧基，烷氧基，环烷基，芳烷基，烷氧基羰基，芳基或杂芳基，或R 1和R 2与相邻的氮原子一起可以形成饱和或不饱和的杂环或稠合和/或取代的环系，并且所述杂环或所述缩合和/或取代的环系可以含有磺基可以通过使式（II）的胺与式（III）的N-氨基甲酰基 - 苯甲酸硫酰亚胺衍生物反应来制备。所公开的N-酰化组合物包含3至60重量％，优选为5至50重量％的式（III）的亚磺酰亚胺衍生物，为97至40重量％，优选为95至50重量％的溶剂，如果需要，为有机或无机碱。所公开的N-酰化浓缩物包含60至95.5重量％的式（III）的N-酰化剂和4.5至40重量％的添加剂。

9. 发明授权

US4373104A Sulfur-containing isoquinoline derivatives, process for the preparation thereof and pharmaceutical compositions containing them 失效
标题翻译：含硫异喹啉衍生物，其制备方法和含有它们的药物组合物
公开(公告)号：US4373104A
公开(公告)日：1983-02-08
申请号：US164939
申请日：1980-07-01
申请人： Kalman Takacs , Maria H. Papp , Gabor Kovacs , Ilona K. Ajzert , Antal Simay , Peter L. Nagy , Marian E. Puskas , Gyula Sebestyen , Istvan Stadler , Zoltan Sumeghy
发明人： Kalman Takacs , Maria H. Papp , Gabor Kovacs , Ilona K. Ajzert , Antal Simay , Peter L. Nagy , Marian E. Puskas , Gyula Sebestyen , Istvan Stadler , Zoltan Sumeghy
IPC分类号： C07D217/00 , A61K31/47 , A61K31/472 , A61P7/08 , A61P7/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/08 , A61P29/00 , A61P43/00 , C07D217/14 , C07D217/16 , C07D513/04
CPC分类号： C07D513/04 , C07D217/14 , Y10S514/869
摘要： Isoquinolines are disclosed of the formula (I) ##STR1## wherein R independently represents hydrogen, hydroxyl or alkoxy having 1 to 4 carbon atoms,R.sup.1 is hydrogen, alkyl having 1 to 4 carbon atoms and optionally substituted with phenyl, phenyl optionally substituted with one or more halogen or alkoxy group, cyano or carbomoyl,R.sup.2 is phenyl optionally substituted with one or more halogen, alkoxy or carboxyl, or a group of the general formula A ##STR2## wherein R.sup.3 is hydrogen, a straight or branched chained alkyl having 1 to 4 carbon atoms or phenyl,m and n independently represent 0, 1 or 2, with the proviso that m+n is at least 1,R.sup.4 is hydrogen, phenyl, hydroxyl, acyloxy, carboxyl, alkoxycarbonyl having 1 to 6 carbon atoms, carbamoyl, carbazoyl or dialkylamino containing 1 to 6 carbon atoms in the alkyl moiety, orR.sup.2 is a straight or branched chained alkylene group having 1 to 6 carbon atoms, andthe dotted line stands for a further carbon-carbon bond or hydrogen atoms in the 3- and 4-positions of the ring,or salts thereof. The new compounds are potent diuretic agents.
摘要翻译：公开了式（I）的异喹啉（I）其中R独立地表示氢，羟基或具有1至4个碳原子的烷氧基，R 1是氢，具有1至4个碳原子的烷基，任选被苯基取代，苯基任选地被一个或多个卤素或烷氧基取代，氰基或甲酰甲酰基，R 2是任选被一个或多个卤素，烷氧基或羧基取代的苯基或通式A的基团，其中R 3是氢，直链或支链具有1至4个碳原子的烷基或苯基，m和n独立地表示0,1或2，条件是m + n至少为1，R4为氢，苯基，羟基，酰氧基，羧基，具有1至6个碳原子的烷氧基羰基碳原子，氨基甲酰基，咔唑基或在烷基部分含有1至6个碳原子的二烷基氨基，或者R2是具有1至6个碳原子的直链或支链链烯基，虚线代表另外的碳 - 碳键或氢原子在3-和环的4-位，或其盐。新化合物是有效的利尿剂。

10. 发明授权

US5220068A Psychostimulant agent 失效
标题翻译：精神刺激剂
公开(公告)号：US5220068A
公开(公告)日：1993-06-15
申请号：US649239
申请日：1991-01-29
申请人： Jozsef Knoll , Antal Simay , Eva Szinnyei , Eva Somfai , Zoltan Torok , Karoly Mozsolits , Janos Bergmann
发明人： Jozsef Knoll , Antal Simay , Eva Szinnyei , Eva Somfai , Zoltan Torok , Karoly Mozsolits , Janos Bergmann
IPC分类号： A61K31/135
CPC分类号： A61K31/135
摘要： The present invention relates to a pharmaceutical composition comprising as active ingredient a compound of the Formula I ##STR1## wherein R.sup.1 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; phenyl alkyl having 7 to 10 carbon atoms; phenyl; or cycloalkyl comprising 3 to 8 carbon atoms;R.sup.2 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; alkyl comprising 1 to 8 carbon atoms substituted by halogen, hydroxy, alkoxy having 1 to 4 carbon atoms or by one or two phenyl groups; phenyl; or cycloalkyl having 3 to 8 carbon atoms,with the proviso that groups R.sup.1 and R.sup.2 together contain at least three carbon atoms. The invention also relates to a process for the preparation of compounds of the Formula I by methods known per se. The compounds of the Formula I are phychostimulants having a new spectrum of effect which can be used in therapy for increasing psychical activity (learning and retention) and for treating clinical patterns of depression and deficiencies of learning and retention like in Alzheimer's disease, and are void of side effects (e.g. due to catecholamine release) of known stimulants.
摘要翻译：本发明涉及包含作为活性成分的式I化合物（I）的药物组合物，其中R1代表包含1至8个碳原子的直链或支链烷基; 具有7至10个碳原子的苯基烷基; 苯基; 或包含3至8个碳原子的环烷基; R2代表包含1至8个碳原子的直链或支链烷基; 被卤素，羟基，具有1至4个碳原子的烷氧基或一个或两个苯基取代的碳原子数为1〜8的烷基; 苯基; 或具有3至8个碳原子的环烷基，条件是基团R 1和R 2一起含有至少3个碳原子。本发明还涉及通过本身已知的方法制备式I化合物的方法。式I的化合物是具有新的效应谱的phychostimulants，其可用于增加心理活动（学习和保留）的治疗和用于治疗抑郁症的临床模式和学习和保留的缺陷，如阿尔茨海默病，并且是无效的的已知兴奋剂的副作用（例如由于儿茶酚胺释放）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式